Sheriff Muazzam M, Basalib Samaher G, Mereani Maya J, Bakhsh Layali M, Alzamzami Bayan A, Garout Raha M
Medicine, Ibn Sina National College for Medical Studies, Jeddah, SAU.
Cureus. 2022 Dec 20;14(12):e32749. doi: 10.7759/cureus.32749. eCollection 2022 Dec.
Introduction COVID-19 vaccine side effects have a fundamental role in public confidence in the vaccine and its uptake process. Thus far, evidence on vaccine safety has been exclusively obtained from manufacturer-sponsored studies; therefore, this study is designed to assess post-COVID-19 vaccine complications in Makkah province, Saudi Arabia. Method A cross-sectional study included 840 subjects conducted from August to November 2022 to collect data about COVID-19 vaccine side effects. A validated questionnaire was used with 21 multiple-choice items covering demographic data, COVID-19 vaccination type, side effects, and medication used to relieve side effects. The online Raosoft sample size calculator (Raosoft Inc., Seattle, Washington) was utilized for sample size calculation. The Statistical Package for the Social Sciences version 22.0 (IBM Inc., Armonk, New York) was utilized to carry out descriptive statistics. The Shapiro-Wilk test was used to evaluate normal data distribution. Significance of categorized data made by the Pearson's Chi-Squared test and of the vaccination side effects experienced in general wellbeing on a scale of 1-10 by the Kruskal-Wallis test. Result The survey found that most participants in the 18-26 age group were from Jeddah, women, and Saudis. Only 7.1% of participants had comorbidities alone, and 63.1% of participants had previously had COVID-19. The vaccine types used in this study were primarily Pfizer (83.3%), AstraZeneca (9.5%), Moderna (3.6%), and combination vaccines (3.6%). The majority of the participants received vaccination up to the third dose. No side effects were reported by 9.5% of participants, while mild and severe side effects were reported by 90.5% and 23.8% of participants, respectively. Mild side effects included injection site pain, redness, tenderness, or itching (34.5%), fatigue (22.6%), low-grade fever, chills, diarrhea, headache (17.9%), and myalgia (14.3%). Conclusion The majority of the side effects of COVID-19 vaccination were minor reactions (90.5%), but 23.8% were found to be serious side effects, most of which lasted one to three days. More independent studies are needed to investigate gender differences, COVID-19 vaccine efficacy, and the prevalence of side effects in other populations conducted by academic institutions. Additional independent research on vaccine safety is urgently needed to increase public confidence in vaccines and to better understand risk factors for vaccine side effects.
引言
新冠疫苗的副作用在公众对疫苗的信心及其接种过程中起着至关重要的作用。到目前为止,关于疫苗安全性的证据完全来自制造商赞助的研究;因此,本研究旨在评估沙特阿拉伯麦加省接种新冠疫苗后的并发症情况。
方法
一项横断面研究纳入了2022年8月至11月期间的840名受试者,以收集有关新冠疫苗副作用的数据。使用了一份经过验证的问卷,其中包含21个多项选择题,涵盖人口统计学数据、新冠疫苗接种类型、副作用以及用于缓解副作用的药物。使用在线Raosoft样本量计算器(Raosoft公司,华盛顿州西雅图)进行样本量计算。利用社会科学统计软件包第22.0版(IBM公司,纽约州阿蒙克)进行描述性统计。使用夏皮罗-威尔克检验评估数据的正态分布。通过Pearson卡方检验对分类数据进行显著性分析,并通过Kruskal-Wallis检验对总体健康状况中1至10级的疫苗接种副作用进行显著性分析。
结果
调查发现,年龄在18 - 26岁组的大多数参与者来自吉达,为女性且是沙特人。只有7.1%的参与者仅患有合并症,63.1%的参与者此前感染过新冠。本研究中使用的疫苗类型主要是辉瑞(83.3%)、阿斯利康(9.5%)、莫德纳(3.6%)和联合疫苗(3.6%)。大多数参与者接种了第三剂疫苗。9.5%的参与者未报告任何副作用,而分别有90.5%和23.8%的参与者报告了轻度和重度副作用。轻度副作用包括注射部位疼痛、发红、压痛或瘙痒(34.5%)、疲劳(22.6%)、低热、寒战、腹泻、头痛(17.9%)和肌痛(14.3%)。
结论
新冠疫苗接种的大多数副作用为轻微反应(90.5%),但发现23.8%为严重副作用,其中大多数持续一至三天。需要更多独立研究来调查性别差异、新冠疫苗的疗效以及学术机构在其他人群中副作用的发生率。迫切需要开展更多关于疫苗安全性的独立研究,以增强公众对疫苗的信心并更好地了解疫苗副作用的风险因素。